ReviewHaematologica2009
How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.
Review in Haematologica, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 41 citations in OpenAlex.
- PCR-based amplification of circulating RNAs as prognostic and predictive biomarkers - Focus on neuroblastoma.Practical laboratory medicine · 2017Article
- CD5 Positive B Lymphoblastic Leukemia: Report of a Case with Review of Literature.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2016Article
- Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.Mediterranean journal of hematology and infectious diseases · 2016Review
- Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia.Seminars in hematology · 2015Review
- Quantitative detection of the human cervical cancer oncogene for monitoring the minimal residual disease in acute leukemia.Experimental biology and medicine (Maywood, N.J.) · 2015Article
- Asymmetric-detection time-stretch optical microscopy (ATOM) for ultrafast high-contrast cellular imaging in flow.Scientific reports · 2014Article
- Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosis.PloS one · 2014Article
- Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.Bone marrow transplantation · 2013Article
- Single molecule quantitation and sequencing of rare translocations using microfluidic nested digital PCR.Nucleic acids research · 2013Article
- Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting.Blood cancer journal · 2013Article
- Minimal residual disease in acute myeloid leukaemia.Nature reviews. Clinical oncology · 2013Review
- How to assess minimal residual disease in pediatric and adult acute myeloid leukemia?Translational pediatrics · 2013Article
- Review
- Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia.Advances in hematology · 2011Article
- The European LeukemiaNet: achievements and perspectives.Haematologica · 2011Article
- Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease.Haematologica · 2010Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to therapeutic agents is a major factor in the failure of cancer treatments. In leukemia, the resistant cells remaining in the bone marrow and/or peripheral blood constitute minimal residual disease and are detectable by highly sensitive assays when the patient appears to be in complete remission. Early detection of the expansion of residual cells permits clinical intervention with the aim of reversing the proliferation of resistant leukemic cells. Therefore, accurate and precise measurement of minimal residual disease can greatly enhance optimization of oncology patients' clinical management. This notion is supported by a large body of data among chronic myeloid leukemia patients, but minimal residual disease detection and monitoring is increasingly applied to other types of leukemia, and is starting to be a factor in decision-making for some therapeutic trials in childhood acute lymphoblastic leukemia. Here, from the solid ground of minimal residual disease detection in chronic myeloid leukemia, the current state of the art and development of molecular techniques in other leukemias and the growing field of multiparameter flow cytometry are reviewed in two separate parts reporting on the respective advances, advantages and pitfalls of these emerging methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.